Physician profile
Brian Emm
NPI 1043315021
$1,291.01
in general payments reported to CMS, 2019-2025
14 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.29 · 2022: $92.31 · 2023: $258 · 2024: $631 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $517.65 | 2022-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $167.46 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $147.52 | 2023-2024 | Azstarys |
| Sanofi Pasteur INC. | $89.12 | 2023-2025 | |
| Pfizer INC. | $88.78 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $53.66 | 2025 | |
| Seqirus USA INC | $45.10 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Glaxosmithkline, LLC. | $41.17 | 2023-2025 | Bexsero, Penmenvy |
| Kaleo, INC. | $37.90 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $35.69 | 2023-2024 | Jornay Pm |
| Acadia Pharmaceuticals INC | $21.34 | 2024 | Daybue |
| Biomarin Pharmaceutical INC. | $19.05 | 2024 | Voxzogo 1.2mg |
| Nestle Healthcare Nutrition INC. | $14.42 | 2023 | |
| Arbor Pharmaceuticals, INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Emm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.